DBTX

Decibel Therapeutics, Inc. [DBTX] Stock Forecast

Q: What is Decibel Therapeutics, Inc. stock symbol ?

Decibel Therapeutics, Inc. is a US stock, located in Boston of Ma and trading under the symbol DBTX

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

DBTX Stock Summary

DBTX has more than 2 years of cash runway (29 months)

EPS has been decreasing for the past 3 years (Yearly statements)

Top 10 Correlated Stocks

DBTX

In the News

06:32 27 Sep 2023 DBTX

Decibel Therapeutics' CVR Appears Around Fair Value

Decibel Therapeutics is being acquired by Regeneron for a cash consideration of $4/share and a CVR linked to DB-OTO. DB-OTO is a gene therapy for hearing loss, with a phase 1/2 trial underway. The CVR broadly pays out with the early stages of the Phase III trial and subsequently the filing of a BLA application (or European equivalent).

12:35 27 Sep 2023 DBTX

Decibel Therapeutics Shares Soar on Acquisition by Regeneron Pharmaceuticals

Shares of Decibel Therapeutics skyrocketed after Regeneron Pharmaceuticals agreed to buy the biotech firm for up to $213 million to expand its gene therapy pipeline.

10:00 27 Sep 2023 DBTX

Decibel Therapeutics (DBTX) Stock Skyrockets 71% on Regeneron Deal

Decibel Therapeutics (NASDAQ: DBTX ) stock is soaring higher on Wednesday after signing a deal with Regeneron Pharmaceuticals (NASDAQ: REGN ). This deal has Regeneron Pharmaceuticals agreeing to acquire Decibel Therapeutics for $4 per share in cash.

09:43 27 Sep 2023 DBTX

Decibel Therapeutics shoots up 72% on Regeneron bid

Shares of Boston's Decibel Therapeutics Inc soared 72% in the first minutes of trading after Regeneron Pharmaceuticals weighed looks calculated to be a knock-out bid for the tiny drug developer. The deal values Decibel Therapeutics, which is working on treatments aimed at enhancing and restoring hearing and balance, at $109 million.

07:55 27 Sep 2023 DBTX

Regeneron buying small cap Decibel Therapeutics for $4 a share

Regeneron Pharmaceuticals Inc. REGN, +0.72% said Wednesday it would pay $4 a share for Decibel Therapeutics Inc. DBTX, +1.09%, a 43% premium over its closing price of $2.79 a share in the previous session. Boston-based Decibel Therapeutics is a clinical-stage biotechnology company with a focus on discovering and developing transformative treatments to restore and improve hearing and balance.

04:30 27 Sep 2023 DBTX

Decibel Therapeutics to Present DB-020 Phase 1b Clinical Trial Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

Data from interim analysis support DB-020 as a potential therapy to protect patients against irreversible hearing loss associated with cisplatin chemotherapy Data from interim analysis support DB-020 as a potential therapy to protect patients against irreversible hearing loss associated with cisplatin chemotherapy

04:30 27 Sep 2023 DBTX

Decibel Therapeutics to Present at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting

BOSTON, May 10, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that it will present at the American Society of Gene and Cell Therapy (ASGCT) 25th Annual Meeting, being held in Los Angeles, California May 16 – 20th, 2023.

07:00 27 Sep 2023 DBTX

Decibel Therapeutics to Present at the 46th Annual Association for Research in Otolaryngology (ARO) MidWinter Meeting

BOSTON, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that it will present findings from its drug discovery and development programs at the 46th Annual MidWinter Meeting of the Association for Research in Otolaryngology (ARO), being held in Orlando, Florida February 11–15, 2023.

07:00 27 Sep 2023 DBTX

Decibel Therapeutics to Participate in Upcoming Investor Conferences

BOSTON, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today announced that Laurence Reid, Ph.D., Chief Executive Officer, will be participating in the following upcoming investor conferences in September.

01:28 27 Sep 2023 DBTX

Top Penny Stocks Today? 3 You Might Want To Watch Before Next Week

Penny stocks to watch before the end of the week. The post Top Penny Stocks Today?

DBTX Financial details

Company Rating

Neutral

Market Cap

123.37M

Income

-63.39M

Revenue

Book val./share

2.13

Cash/share

3.13

Dividend

Dividend %

Employees

Optionable

Shortable

Yes

Earnings

07 Nov 2023

P/E

-1.94

Forward P/E

PEG

-2.89

P/S

P/B

2.3

P/C

1.57

P/FCF

-2.5

Quick Ratio

2.95

Current Ratio

3.03

Debt / Equity

0.24

LT Debt / Equity

0.17

EPS (TTM)

-2.54

EPS next Y

EPS next Q

EPS this Y

5.88%

EPS next Y

EPS next 5Y

EPS last 5Y

Revenue last 5Y

Revenue Q/Q

EPS Q/Q

37.74%

SMA20

SMA50

66.67%

SMA100

66.67%

Inst Own

61.56%

Inst Trans

ROA

-67%

ROE

-84%

ROC

-0.97%

Gross Margin

Oper. Margin

Profit Margin

Payout

Shs Outstand

25.13M

Shs Float

13.34M

Target Price

52W Range

1.61-5.4

52W High

-1.8%

52W Low

+391%

RSI

Rel Volume

5.96

Avg Volume

211.63K

Volume

1.26M

Perf Week

-3.73%

Perf Month

-3.91%

Perf Quarter

52.96%

Perf Half Y

76.62%

Beta

-0.436328

Volatility

0.04%, 0.08%

Prev Close

Price

4.91

Change

-0.2%

DBTX Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
Revenue per share	0	0	0	0	0
Net income per share	-4.98	-5.61	-1.63	-2.38	-2.52
Operating cash flow per share	-4.97	-6.72	-1.41	-1.99	-2.28
Free cash flow per share	-5.15	-6.81	-1.42	-2.02	-2.3
Cash per share	11.33	4.39	2.35	6.84	4.19
Book value per share	7.92	2.15	-7.04	6.52	3.28
Tangible book value per share	7.92	2.15	-7.04	6.52	3.28
Share holders equity per share	7.92	2.15	-7.04	6.52	3.28
Interest debt per share	0	0	0.22	0.2	0.61
Market cap	130.85M	132.63M	416.94M	101.06M	51.17M
Enterprise value	119.53M	114.03M	389.39M	64.82M	30.61M
P/E ratio	-3.62	-3.21	-11.08	-1.95	-0.81
Price to sales ratio	0	0	0	0	0
POCF ratio	-3.63	-2.68	-12.77	-2.34	-0.9
PFCF ratio	-3.5	-2.65	-12.66	-2.3	-0.89
P/B Ratio	2.28	8.37	-2.56	0.71	0.63
PTB ratio	2.28	8.37	-2.56	0.71	0.63
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	-3.29	-2.69	-9.84	-1.33	-0.49
EV to operating cash flow	-3.31	-2.31	-11.92	-1.5	-0.54
EV to free cash flow	-3.2	-2.27	-11.82	-1.48	-0.53
Earnings yield	-0.28	-0.31	-0.09	-0.51	-1.23
Free cash flow yield	-0.29	-0.38	-0.08	-0.43	-1.12
Debt to equity	0	0	-0.03	0.03	0.17
Debt to assets	0	0	0.08	0.02	0.11
Net debt to EBITDA	0.31	0.44	0.7	0.74	0.33
Current ratio	7.6	3.55	2.98	7.99	4.81
Interest coverage	0	0	0	0	-53.66
Income quality	1	1.16	0.83	0.83	0.9
Dividend Yield	0	0	0.13	0.27	0
Payout ratio	0	0	-1.46	-0.53	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.04	0.01	0.01	0.02	0.01
Capex to revenue	0	0	0	0	0
Capex to depreciation	-0.87	-0.41	-0.17	-0.53	-0.32
Stock based compensation to revenue	0	0	0	0	0
Graham number	29.79	16.49	16.05	18.7	13.64
ROIC	-0.69	-2.69	0.24	-0.36	-0.58
Return on tangible assets	-0.39	-0.96	-0.56	-0.28	-0.51
Graham Net	6.4	0.72	-7.56	5.27	2.52
Working capital	72.61M	24.12M	38.45M	143.65M	85.59M
Tangible asset value	57.45M	15.85M	-162.69M	141.69M	81.79M
Net current asset value	47.78M	6.58M	-172.15M	121.4M	66.45M
Invested capital	0	0	-0.03	0.03	0.17
Average receivables	0	0	618.5K	6.32M	5.7M
Average payables	0	1.04M	1.57M	3.07M	2.54M
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.63	-2.6	0.23	-0.37	-0.77
Capex per share	-0.18	-0.1	-0.01	-0.03	-0.02

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric	2022-06-30	2022-09-30	2022-12-31	2023-03-31	2023-06-30
Revenue per share	0	0	0	0	0
Net income per share	-0.68	-0.64	-0.64	-0.53	-0.73
Operating cash flow per share	-0.54	-0.55	-0.31	-0.68	-0.41
Free cash flow per share	-0.54	-0.55	-0.32	-0.69	-0.41
Cash per share	5.03	4.48	4.19	3.52	3.13
Book value per share	4.48	3.88	3.28	2.79	2.13
Tangible book value per share	4.48	3.88	3.28	2.79	2.13
Share holders equity per share	4.48	3.88	3.28	2.79	2.13
Interest debt per share	0.62	0.6	0.59	0.51	0.51
Market cap	105.08M	86.37M	51.17M	75.47M	96.32M
Enterprise value	64M	64.41M	30.61M	50.8M	69.36M
P/E ratio	-1.54	-1.35	-0.8	-1.42	-1.33
Price to sales ratio	0	0	0	0	0
POCF ratio	-7.84	-6.3	-6.59	-4.42	-9.38
PFCF ratio	-7.77	-6.28	-6.43	-4.36	-9.39
P/B Ratio	0.94	0.89	0.63	1.08	1.81
PTB ratio	0.94	0.89	0.63	1.08	1.81
EV to sales	0	0	0	0	0
Enterprise value over EBITDA	-3.82	-4.03	-1.9	-3.69	-3.71
EV to operating cash flow	-4.77	-4.7	-3.94	-2.98	-6.76
EV to free cash flow	-4.73	-4.68	-3.84	-2.93	-6.76
Earnings yield	-0.16	-0.19	-0.31	-0.18	-0.19
Free cash flow yield	-0.13	-0.16	-0.16	-0.23	-0.11
Debt to equity	0.14	0.15	0.17	0.19	0.24
Debt to assets	0.1	0.1	0.11	0.12	0.14
Net debt to EBITDA	2.45	1.37	1.28	1.79	1.44
Current ratio	6.18	5.4	4.81	4.14	3.03
Interest coverage	-180.03	-43.71	-24.98	18.68	0
Income quality	0.79	0.86	0.49	1.28	0.57
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0	0	0	0	0
Research and developement to revenue	0	0	0	0	0
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.01	0	0.03	0.02	0
Capex to revenue	0	0	0	0	0
Capex to depreciation	-0.33	-0.13	-0.53	-0.78	0.04
Stock based compensation to revenue	0	0	0	0	0
Graham number	8.3	7.48	6.86	5.79	5.9
ROIC	-0.12	-0.13	-0.15	-0.15	-0.24
Return on tangible assets	-0.11	-0.11	-0.13	-0.12	-0.19
Graham Net	3.47	2.96	2.52	2.03	1.49
Working capital	118.53M	102.91M	85.59M	72.69M	53.87M
Tangible asset value	111.86M	96.81M	81.79M	69.84M	53.31M
Net current asset value	94.99M	80.83M	66.45M	55.26M	39.37M
Invested capital	0.14	0.15	0.17	0.19	0.24
Average receivables	10M	10M	5M	2.2M	2.2M
Average payables	1.56M	2.47M	2.05M	1.17M	947.5K
Average inventory	0	0	0	0	0
Days sales outstanding	0	0	0	0	0
Days payables outstanding	0	0	0	0	0
Days of inventory on hand	0	0	0	0	0
Receivables turnover	0	0	0	0	0
Payables turnover	0	0	0	0	0
Inventory turnover	0	0	0	0	0
ROE	-0.15	-0.17	-0.19	-0.19	-0.34
Capex per share	0	0	-0.01	-0.01	0

DBTX Frequently Asked Questions

What is Decibel Therapeutics, Inc. stock symbol ?

Decibel Therapeutics, Inc. is a US stock , located in Boston of Ma and trading under the symbol DBTX

What is Decibel Therapeutics, Inc. stock quote today ?

Decibel Therapeutics, Inc. stock price is $4.91 today.

Is Decibel Therapeutics, Inc. stock public?

Yes, Decibel Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 211.63K
Market Capitalization 123.37M
Employee 68
CEO Dr. Laurence E. Reid Ph.D.
Headquarters Boston,MA,US
IPO Date 2021-02-12
Website https://www.decibeltx.com

Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. Its product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. The company's lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. It is also developing DB-ATO and AAV.201, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the vestibule; DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial; AAV.103 to restore hearing in individuals with a gap junction beta-2 (GJB2) deficiency; AAV.104 to restore hearing in individuals with stereocilin (STRC) deficiency; and cochlear hair cell regeneration program, an AAV-based gene therapy that utilizes cell-selective expression of reprogramming factors to convert supporting cells into outer hair cells. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts.